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Abstract
This study aimed to estimate the prevalence of three measures of multimorbidity among people aged 50 years or older
in England. Beside the basic measure of two or more diseases within a person, we added a measure of three or more
affected body systems (complex multimorbidity) and a measure of 10 or more functional limitations. We found that the
three health outcomes became more prevalent between 2002 and 2015. They were more common among females than
males and were becoming more common among younger age groups. While in 2002, the prevalence of basic multi-
morbidity overcame 50% from the 70–74 age group upwards, in 2015 it crossed the same threshold in the 65–69 age
group. The distribution of multimorbidity and multiple functional limitations were stratified by the amount of household
wealth. Multiple functional limitations reflected the largest differences between the most and the least affluent groups
(5.9-fold in 2014/2015), followed by the measure of complex multimorbidity (2.8-fold in 2014/2015) and basic multi-
morbidity (1.9-fold) in 2014/2015.While age acted as a levelling factor for the wealth differences in basic multimorbidity, it
had no such effect on the two other outcomes. Our study observed social polarization among multimorbid ageing population
in England where complex multimorbidity and multiple functional limitations increase faster and reflect stronger inequality
than basic multimorbidity.
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Background
Multimorbidity (MM) when defined as the co-occurrence of
two or more diseases within a person1 is rising globally.2,3 Its
prevalence among people aged 65 years or older in England is
projected to rise from 54% in 2015 to 67.8% in 2035.4 People
will live longer but in worse health. The extra years lived with
MM will lead to higher utilization of primary and secondary
healthcare.4 The definition of MM as two or more diseases
underpinning these statistics has been criticized for leading to
prevalence estimates in the elderly population which are too
high (55–98% between studies) to be able to predict patients
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with higher need.5,6 Practitioners need a measure of MM that
can reflect the biology of ageing and identify elderly popula-
tions with higher healthcare needs.
Harrison et al.7 introduced the concept of complex mul-
timorbidity (CMM), defined as ‘the co-occurrence of three
or more chronic conditions affecting three or more different
body systems within one person without an index chronic
condition’.7 Compared to the basic definition of two or
more conditions, the construct of CMM leads to lower
prevalence estimates and it has been proposed that it might
better identify patients with higher needs.6,7 We argue that
CMM might also be better at reflecting the biology of
ageing since it characterizes a simultaneous breakdown
or dysfunction of several distinct pathologies or body
systems.8,9 The affected body systems of people aged 65
or older were found as predictors of the total number of
hospital stays and of the number of hospital admissions.10
The process of ageing manifests itself not just in the
number of morbidities an individual has but also in physical
functioning. A measure of multiple functional limitations
(MFLs) was included as our third health outcome. Its pur-
pose is to identify the impact of MM on the combined
functioning of ageing people. Some conditions (e.g. high
blood pressure) may have no effect on the physical func-
tioning but others do, such as arthritis. MM predicts a
decline in physical functioning among ageing people,11,12
which has implications for quality of life, need for health-
care, residential care and premature mortality.11–13 Mea-
suring MFLs also responds to the fact that the proportion
of old people with impairments and limitations in several
body systems increases with age.12,14
Socio-economic status (SES) is a major determinant of
health inequalities. Studies which explored the association
between MM and SES focused on area deprivation,15–17
income,18 occupational status19 and education.18,20 Regard-
less of the type of measure, MM is more common among
people with lower SES, even when controlling for age and
sex. However, all of these studies focus on the simple def-
inition of MM that may hide the nuances of relationships
and the true underlying scale of inequalities.
Our study is the first population-level analysis that dif-
ferentiates the prevalence of MM by complexity and degree
of functional limitation as well as their variation by key
modifying factors. The study has two aims: (1) to compare
temporal trends in the prevalence of basic MM, CMM and
MFLs in an ageing population in England and (2) to exam-
ine the variation in their prevalence by age, sex and SES.
Methods
Data and study population
We used data from the English Longitudinal Study of
Ageing (ELSA) which is a panel study with a range of
social, economic, psychological, cognitive and health data.
It is based on a representative sample of people living in
England aged 50þ years. It commenced in 2002 and is
followed up every 2 years. The data used in this analysis
was collected via personal interviews and the study
response rate at wave 7 was 61%.21 The baseline sample
consisted of 12,099 members. This analysis uses data from
the core sample members who were recruited at either the
first wave or at any of the refreshment samples at waves 3,
4, 6 and 7.22 The effects of clustering and stratification in a
complex sample design such as ELSA were taken into
account using wave-specific weights. The weights include
a scaling factor to make sure that the original sample and
refreshment samples are as equally proportional with
respect to age as in the general population.21
Measures of health
ELSA records data on a range of physical and mental health
conditions. Twenty five of these variables were consis-
tently recorded at each wave and are used to measure mul-
tiple health conditions in this study (Table 1). This includes
the most common conditions among the elderly (diabetes,
hypertension, stroke, cancer and depression), as found by a
systematic literature review.23
Participants were asked whether they still had the
condition diagnosed by a doctor that they had reported
previously and if not whether they could report a new con-
dition. We have grouped health data into three categories:
individual morbidities, groups representing body systems
and functional limitations (Table 1). Adapting Verbrugge
and Jette’s disablement process framework,24 instances of
impairment (dysfunction and abnormalities in body sys-
tems) and disability (difficulty with daily activities) were
included within the category of ‘functional limitations’
(restrictions in basic physical and mental actions).
Measure 1: Multimorbidity
We created a binary variable which identified people at
each wave who had two or more morbidities as listed in
Table 1. The list includes a few symptoms such as halluci-
nations which do not represent a condition but can be used
as a proxy for schizophrenia or another condition
(e.g. alcohol dependency).25 In a similar way, emotional
problems and mood swings are used as indicators of either
mild anxiety and depression or possibly manic depressive
tendencies26 but the clinician has chosen not to use the
more formal diagnostic label, for whatever reason. The
information on whether an individual has or has not got a
chronic disease was composed of the data fed forward from
the previous wave of observation and from the information
on the newly reported cases of disease.
Measure 2: Complex multimorbidity
Following the definition of CMM by Harrison et al.,7 we
identified individuals with three or more body systems
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affected by disease as having CMM. Body systems were
defined and represented by the chapters of the International
Classification of Diseases 10th Revision system (Table 1).
Measure 3: Multiple functional limitations
The third health outcome was based on the combination
of general mobility variables, activities of daily living
(ADL) variables and data on symptoms of chronic con-
ditions (Table 1). ADL is used to measure functional
capacity and it concerns the abilities necessary for basic
functioning, as well as functions necessary for living in
a community.27 Most studies have explored prevalence
and effects of either single impairments and functional
limitations or their combinations in ADL or instrumental
ADL, but we decided to examine their combined burden
by summing all of them up including the symptoms.
Difficulties with walking were captured with three dis-
tinct variables (having difficulty walking 0.25 mile,
walking 100 yards and walking across a room) which,
if combined, reflect the degree of severity. For example,
a person who has got all three difficulties is more func-
tionally limited than a person with only one of them.
The total number of functional limitations per individual
was summed up. Based on the exhaustive list of 29
limitations, the frequencies of MFLs were high, reflect-
ing the older age of participants. To identify the parti-
cipants with the highest level of disability we decided to
set a cut-off point of 10 or more functional limitations
within the same person.
Covariates
Age
Age was categorized into 5-year bands, from 50–54 up
to 80–84 years of age. The age of persons aged 85 and
older was collapsed in one category 85þ due to small
sample size.
Sex
Sex is an important determinant of health. Previous studies
have shown that while women in most countries have a
longer life expectancy than men, they are more likely to
be affected by a number of chronic diseases.5,28,29
Table 1. Health data used to measure basic multimorbidity, complex multimorbidity and multiple functional limitations.
Morbidities Body systems Functional limitations
1 High blood pressure 1. Eye disorders General mobility
2 Angina 1.1. Glaucoma 1 Walking 100 yards
3 Congested heart failure 1.2. Macular degeneration 2 Sitting for 2 h
4 Heart murmur 1.4. Cataracts 3 Getting up from chair
5 Abnormal heart rhythm 2. Circulatory disorders 4 Climbing several flights of stairs
6 Heart attack 2.1. High blood pressure 5 Climbing one flight of stairs
7 Diabetes 2.2. Angina 6 Stooping, kneeling or crouching
8 Stroke 2.3. Heart attack 7 Reaching arms above shoulders
9 Lung disease 2.4. Congestive heart failure 8 Pulling or pushing a chair
10 Asthma 2.5. Heart murmur 9 Lifting/carrying weights over 10 pounds
11 Arthritis 2.6. Abnormal heart rhythm 10 Picking up a 5p coin
12 Osteoporosis 2.7. Stroke Activities of daily living
13 Cancer 3. Endocrine, nutritional and metabolic 11 Dressing, including putting on shoes and socks
14 Parkinson’s disease 3.1. Diabetic eye disease 12 Walking across a room
15 Dementia 3.2. Diabetes 13 Bathing or showering
16 Alzheimer’s disease 4. Musculoskeletal and connective system 14 Eating, such as cutting up your food
17 Hallucinations 4.1. Osteoporosis 15 Getting in or out of bed
18 Anxiety 4.2. Arthritis 16 Using the toilet, including getting up or down
19 Depression 5. Respiratory 17 Using a map to figure out how to get around
20 Emotional problems 5.1. Lung disease 18 Preparing a hot meal
21 Mood swings 5.2. Asthma 19 Shopping for groceries
22 Glaucoma 6. Neoplasms 20 Making telephone calls
23 Diabetic eye disease 6.1. Cancers 21 Taking medications
24 Macular degeneration 7. Nervous disorders 22 Doing work around the house or garden
25 Cataracts 7.1. Parkinson’s disease 23 Managing money (paying bills, track of expenses)
7.2. Alzheimer’s disease Symptoms
7.3. Hallucinations 24 Difficulty walking 0.25 mile
8. Mental and behavioural 25 Pain in general
8.1. Anxiety 26 Problems with eyesight
8.2. Depression 27 Problems with hearing
8.3. Emotional problems 28 Balance on level surface
8.4. Mood swings 29 Dizzy walking on level surface
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Socio-economic status
SES was measured using quintiles of net total household
wealth. Household wealth embodies access to financial
resources accumulated during life and therefore reflects
social status at later life.30,31 The net household wealth is
defined as the sum of savings, investments, physical wealth
and housing wealth after financial debt and mortgage debt
have been subtracted. It is based on 22 distinct components
of wealth and debt.21 The wealth intervals in £s between
2002 and 2015 are presented in Online Supplementary
Material B, Table B.4. While the median value of house-
holds increased in 2002–2015 from £100,000 to £190,000,
most change was due to the outlier values in the poorest and
the richest quintiles.
Statistical analysis
Descriptive analyses of the study population included sum-
mary statistics to explore general patterns. Data were
weighted for non-response, stratification and clustering
effects. The variation in the size of the age groups
decreased over time for age groups of older people, but the
pattern nevertheless justified the need for age standardiza-
tion between waves (Online Supplementary Material A).
The prevalence was standardized to the age distribution
of the population at wave 1 in 2002, to allow for more
robust comparison of trends over time. Standardization also
helps our results to remain representative of national pat-
terns improving their generalizability.
We have conducted repeated cross-sectional analyses of
prevalence at a population level. Prevalence estimates were
stratified by age groups, sex and wealth quintiles, to
observe the distribution of outcomes by selected covariates.
We then checked for consistency and interaction effects
of Time  SES and Age  SES by merging the waves of
measurement into a panel dataset. This allowed us to com-
pare the estimates from cross-sectional analyses with two
multilevel logistic regression models, taking into account
temporal correlation within individuals. The results were
plotted graphically using marginal effects at representative
values. All analyses were conducted in Stata version 13.
Results
General characteristics of the study population
The general characteristics of the studied population are
shown in Table 2. The number of participants varied
between 11,391 (2002/2003) and 8249 (2014/2015). The
median age in 2002/2003 was 64 (interquartile range (IQR)
56–73) and it increased to 67 years in 2014/2015 (IQR
61–75). The proportion of the oldest old people, aged 85
or more, was between 5.2% in 2002/2003 and 5.7% in
2014/2015. The proportion of women was higher than the
proportion of men (53.1%) on average during the period
2002–2015. T
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Trends in the prevalence of our measures of MM
Figure 1 summarizes trends in the prevalence of basic MM,
CMM and MFLs. The prevalence of MM grew from 41.6%
in 2002/2003 to 46.6% in 2014/2015. The prevalence of
CMM grew from 12.2% in 2002/2003 to 21.1% in 2014/
2015. This is a larger change relative to the baseline esti-
mate than the growth of basic MM. The prevalence of
MFLs rose from 9.6% in 2002/2003 to 14.3% in 2014/
2015 which is larger than the growth of basic MM. Given
our knowledge of the nature of functional limitation as a
consequence of MM,11,12 we would expect a larger relative
change in this outcome than in either of the multimorbid-
ities. Hence, we examined developments for each compo-
nent subgroup (general mobility, ADLs and symptoms)
separately and found similar flat trend for each of them
(Online Supplementary Material E, Figure 7).
Figure 2 shows the distribution of the three health out-
comes by sex over time. The comparison between sexes
shows that regardless of the measure of MM or specific
time point, on average a higher proportion of women have
MM than men. The difference in the change of prevalence
between sexes over time was only marginal with the only
exception being in CMM. The prevalence for males more
than doubled at the end of the followed period while the
prevalence of CMM for females grew only 1.6 times.
Prevalence of the three measures of MM by
age group
We next explored how the prevalence varied within age
bands for each measure. The prevalence of both types of
MM and of MFLs at each time point increased with age
(see Online Supplementary Material B, Tables B.1–B.3).
The difference in prevalence of MM between the youngest
(aged 50–54) and the oldest group (aged 85þ) ranged
between threefold in wave 2012/2013 and fourfold in wave
2004/2005 (Online Supplementary Material B, Table B.1).
The majority of participants were multimorbid when and
after reaching the 70–75 age group. From 2012/2013, this
threshold shifted to the 65–69 age band.
The difference in the prevalence of CMM between the
youngest and the oldest group ranged between 4.6 times in
2010/2011 and 8.8 times in wave 2004/2005 (Online Sup-
plementary Material B, Table B.2). The variation in pre-
valence levels by age is larger in the complex than basic
MM. The difference in the prevalence of 10þ functional
limitations between the youngest and the oldest group ran-
ged between 3.9 times in wave 2010/2011 and 7.2 times in
2014/2015 (Online Supplementary Material B, Table B.3).
Prevalence of both CMM and 10þ MFLs remained under
50% within each age group.
Stratification of prevalence by SES
Regardless of the outcome, clear differences between the
socio-economic groups were observed (Figure 3). Preva-
lence of MM, CMM and MFLs was graded by each wealth
quintile with people in the poorest quintile having the high-
est prevalence and people in the wealthiest quintile having
the lowest. The measure of the MFLs captured the largest
relative differences between the most and the least affluent
groups (5.9-fold in 2014/2015), followed by the measure of
CMM (2.8-fold in 2014/2015). The relative difference was
the smallest for basic MM (1.9-fold) in 2014/2015. The
interaction between time and household wealth was tested
in a logistic marginal effects model and the results agreed
with the stratified distribution of the prevalence (Online
Supplementary Material C).
We further stratified each age band by quintiles of
household wealth to observe differences in prevalence of
our measures (Figure 4).To avoid data clutter, we report
only results for the observation in 2014/2015. We found the
largest variation in the 50–54 age group. The prevalence of
basic MM in the poorest quintile was 4.1-times higher than
in the richest quintile in the youngest age group. People
aged 50–54 years in the poorest quintile had levels of MM
equivalent to people 15–20 years older in the most affluent
quintile. The prevalence of CMM and MFLs in the poorest
category was 18.7-times and 14-times higher than in the
wealthiest category in the youngest age group. People aged
50–54 years in the poorest quintile had levels of MM equiv-
alent to people 20 years older (for CMM) and 30 years
older (for MFLs) in the most affluent quintile.
The patterns in Figure 4 indicated that the effect of age
on the prevalence estimates varies by SES. The interaction
effect for the whole period 2002–2015 was further explored
in a logistic regression model. The marginal effects (see
Online Supplementary Material D, Figure 6) show changes
in the probability of an outcome as the values of the house-
hold wealth variable change between quintiles. The addi-
tional effect of change in wealth quintile on the probability
of having MM in 2014/2015 was the strongest in the lowest
wealth quintile up to the age of 80–84. An overall pattern
for all quintiles represents a socio-economic gradient up to
Figure 1. Age-standardized prevalence of basic multimorbidity,
complex multimorbidity and multiple functional limitations for
England, 2002–2015 (95% CIs). CI: confidence interval.
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the age of 75–80. For older age groups, the effects overlap
and no pattern is discernible any more. The pattern changes
for people with MFLs. The graded differences in effects
between quintiles are more pronounced and they remain
distinct even in the oldest age category. This confirms the
distribution for 2014/2015 identified in Figure 4.
Discussion
Key results
Our study found that the prevalence of basic MM, CMM
and MFLs in the ageing population of England increased
between 2002/2003 and 2014/2015. We standardized our
analysis to remove differences in age structure over time
but in absolute terms, this increase will be even larger due
to the ageing population. Also the addition of refreshment
samples (age 50–53) at waves 3, 4, 6 and 7 has potentially
resulted in an underestimation of the prevalence. The dis-
tribution of these health outcomes at population level was
influenced by sex as they were more common among
women than among men. Age was another determinant of
the distribution. Our health outcomes were becoming more
common in younger age groups during the observed period.
The age when majority of an age group became multimor-
bid shifted from the 70–74 age group to the 65–69 age
Figure 3. Age-standardized prevalence of (a) basic multimorbidity, (b) complex multimorbidity and (c) 10þ multiple functional
limitations by quintiles of household wealth for England, 2002–2015 (95% CIs). CI: confidence interval.
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Figure 2. Age-standardized prevalence of basic multimorbidity, complex multimorbidity and multiple functional limitations by sex for
England, 2002–2015 (95% CIs): (a) males and (b) females. CI: confidence interval.
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group (Online Supplementary Material B, Table B.1). Out
of the three measures, the prevalence of CMM had the
steepest growth, followed by MFLs and basic MM.
Furthermore, the prevalence of MM, CMM and MFLs was
socially stratified. People with less household wealth had
higher levels of multiple health problems than people from
the more affluent wealth quintiles. The disparity in wealth
was larger for CMM and functional limitations than for
basic MM.
We also discovered that SES and age mutually inter-
acted. The differences in the prevalence of basic MM
between the wealth quintiles were the largest in the young-
est age group and they narrowed down as people aged
(Figure 4). The differences in the prevalence of CMM and
especially MFLs between the poorest and wealthiest quin-
tile remained large for all age groups (Figure 4).
The pattern of health inequality based on cross-sectional
stratification analyses in Figures 3 and 4 was confirmed
after data were reshaped into a panel design where time
interacted with wealth (Online Supplementary Material C,
Figure 5) and age interacted with wealth (Online Supple-
mentary Material D, Figure 6).
Interpretation
The rising prevalence of MM consistent across three dif-
ferent conceptualizations between 2002/2003 and 2014/
2015 supports projections of a growing trend.4 Prevalence
in general is shaped by both the rate at which new cases
are occurring and the average duration of disease. Our
analysis was a repeated cross-sectional and as such it
examined neither the incidence nor the duration of
MM and cannot quantify their relative contribution to
the increased prevalence.
Household wealth, an indicator of SES, was negatively
associated with MM and MFLs. This is consistent with
previous studies reporting socio-economic gradient in
MM.15–20,32 Our study observed that the gap between the
wealth quintiles was larger for participants with CMM and
the largest for people with 10 or more functional limita-
tions. Lack of household wealth was related to higher com-
plexity of MM and corresponding limitations and vice
versa. This is consistent with the findings of a study exam-
ining growth in functional limitations and socio-economic
factors.33 It seems plausible that this gradient in complexity
might be explained by problems with the self-management
of MM. Patients whose everyday lives are overwhelmed by
acute social problems are less able to manage the complex
treatment burden and find adequate social support.34 This
would suggest that the true impact of inequalities is under-
estimated if MM is defined as the presence of two or more
conditions or, similarly, if the cut-off measure for number
of functional limitations is set too low.
Ageing with MM and functional limitation was differ-
entiated by SES. We observed an excess of multiple health
problems in the youngest age cohort with lowest SES.
Figure 4. Prevalence of (a) basic multimorbidity, (b) complex multimorbidity and (c) 10þ multiple functional limitations by age band
and wealth quintile for England, 2014/2015 (95% CIs). CI: confidence interval.
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People aged 50–54 years in the poorest quintile had levels
of CMM comparable to those 20 years older in the most
affluent quintile and level of functional limitations compa-
rable to those 30 years older in the top wealth quintile. This
suggests an earlier onset of MM, and especially of CMM
and MFLs, for people with lower SES. Earlier origins of
basic MM in Scotland were observed by Barnett et al.15
The differences in the prevalence between the wealth quin-
tiles were the largest in the youngest age group but they
narrowed down as people aged. Similar levelling effects of
ageing on basic MM prevalence have been reported previ-
ously.15 The differences in the prevalence of CMM and
especially MFLs between the poorest and wealthiest quin-
tile remained large for all age groups. This suggests that
accumulated financial resources at older age can act as a
protective factor against increased disease complexity. One
pathway in which this accumulated financial resources may
protect against increased disease complexity is via finan-
cial advantage translating into an actual healthy behaviour.
For example, Link and Phelan postulated that individuals
from higher social class backgrounds are capable to use
resources such as power, money, knowledge, prestige or
social contacts to either protect themselves from the health
risks or compensate for their existing disease burden.35
Limitations
Our exploratory study focused on the assessment of the
burden of MM, CMM and MFLs at the population level.
Using a repeated cross-sectional design does not allow any
explanatory inferences to be drawn regarding individual
trends or causal relationships between covariates and out-
come variables.
The estimates of prevalence might be underestimated as
they are based on self-reported information on health prob-
lems. A previous study found that prevalence based on self-
reports was lower than if data were obtained from medical
examinations.36 A combination of data sources was sug-
gested as the best way of providing the most reliable results.6
This study could be expanded if we had shown an asso-
ciation between the two MM measures and the measure of
MFLs. Such an analysis might be interesting especially as
both CMM and MFLs represent problems affecting multi-
ple body systems.
Conclusion
To the best of our knowledge, this article is the first study to
examine trends in the prevalence of MM as measured
through three types of conceptualizations of MM. We
uncovered processes of clear polarization within the ageing
population of England. Alongside stable proportion of peo-
ple who were free of any chronic disease and declining
proportion of those with one disease, we observed that the
increase in complexity overtakes the rise in basic MM and
MFLs. Another axis of differentiation is by SES where the
higher household wealth is related to lower prevalence. At
the same time, this process introduces health inequality
within age groups. CMM and MFLs are increasing faster
and capture stronger inequality than the measure of basic
MM. Using different measures of MM can contribute to
identify population groups with higher healthcare needs
and to a better allocation of healthcare resources. Reporting
the patterns of body systems affected by chronic conditions
may help healthcare planners identify services which
should be co-located, for an optimal care of these
patients.37 The CMM measure would also allow identifica-
tion of patients who may need help in coordinating care
between multiple healthcare providers.
Policies aiming to prevent and reduce the growth in MM
should be approaching older population as diverse and take
into account the multiple polarizations we have described.
It would be meaningful to focus the preventive efforts to
younger age groups where social inequality appears to be
more intertwined with chronic complexity and functional
limitation than in older age. The contribution of these
younger cohorts as they age into the older population, along
with growing numbers of the very old, could significantly
increase the health and social care costs in future.
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